ALVOW News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

Loading chart

Pay with

AL

Mkt Cap

N/A

Volume

N/A

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Viðskipti stjórnenda og tengdra aðilaAlvotech secured a $75 million term loan facility maturing December 31, 2027, led by GoldenTree Asset Management. This follows a recent $165 million equity raise, further strengthening the company's cash position and liquidity.GlobeNewswire Inc. · Jul 3, 2026

Transactions of Managers and Closely Associated PersonsAlvotech secured a $75 million term loan facility maturing December 31, 2027, led by GoldenTree Asset Management. This follows a recent $165 million equity raise, further strengthening the company's cash position and liquidity.GlobeNewswire Inc. · Jul 3, 2026

Viðskipti stjórnenda og tengdra aðilaAlvotech successfully closed a public offering raising $165 million in aggregate, with underwriters fully exercising their option to purchase additional shares. The offering included a concurrent private placement where Celtic Lux Holdings purchased 10.133 million shares at $3.75 per share on June 16, 2026.GlobeNewswire Inc. · Jun 22, 2026

Transactions of Managers and Closely Associated PersonsAlvotech closed a public offering raising $165 million in aggregate proceeds, with underwriters fully exercising their option to purchase additional shares. The offering included a concurrent private placement where Celtic Lux Holdings acquired 10,133,333 shares at $3.75 per share.GlobeNewswire Inc. · Jun 22, 2026

Alvotech tilkynnir um verð og úthlutun hlutabréfa að andvirði um 152 milljónir dollara í útboði í Bandaríkjunum og lokuðu útboði til fagfjárfesta á Evrópska efnahagssvæðinuAlvotech (NASDAQ: ALVO) announced a $152 million share offering, comprising an $85 million public offering in the US at $3.75 per share and a $67 million private placement to institutional investors in the EEA. The company plans to use proceeds for biosimilar drug development, working capital, and operational expenses. BofA Securities, Jefferies, and Evercore ISI are joint underwriters.GlobeNewswire Inc. · Jun 16, 2026

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private PlacementAlvotech priced a $152 million public offering of 22.67 million ordinary shares at $3.75 per share, with an additional concurrent private placement of 17.83 million shares at the same price expected to raise approximately $67 million. The company plans to use net proceeds for biosimilar development, working capital, and potential debt repayment. The offering is expected to close on June 17, 2026, with the private placement closing around June 25, 2026.GlobeNewswire Inc. · Jun 16, 2026

Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?Teva Pharmaceutical has rebounded 97% in 12 months driven by its expanding biosimilars lineup and branded drugs like Austedo. However, the stock now trades at a fair 25x P/E ratio with 2026 revenue expected to be flat to lower. While biosimilars could grow to $800 million by 2027, the narrow-margin business faces intense competition and the easy gains may already be priced in. The analyst recommends watching but not buying.The Motley Fool · Jun 12, 2026

Alvotech files Annual Report with the SECAlvotech (NASDAQ: ALVO), an Iceland-based biotechnology company specializing in biosimilar medicines, has filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission. The company has five approved and marketed biosimilars and nine additional candidates in development across multiple therapeutic areas.GlobeNewswire Inc. · Mar 30, 2026

Alvotech birtir ársreikning á eyðublaði 20-FAlvotech announced the publication of its 2025 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The report is available on the SEC website and Alvotech's investor relations page.GlobeNewswire Inc. · Mar 30, 2026

Alvotech Publishes 2025 Annual ReportAlvotech (NASDAQ: ALVO), an Iceland-based biotechnology company specializing in biosimilar medicines, has published and filed its 2025 Annual Report with the SEC on Form 20-F. The company currently has five approved and marketed biosimilars and nine additional candidates in development across multiple therapeutic areas.GlobeNewswire Inc. · Mar 30, 2026

to start trading

AL

ALVOWAlvotech Warrant

ALVOW

Pay with—

Available Balance0.00

Your PositionYou don't own any ALVOW yet.

Related Tickers

Earnings